Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events-Reference-Cited by-同舟云学术

Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events

Published:2021-10 Issue:10 Volume:16 Page:1759-1764
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Luo Jia^ORCID,Beattie Jason A.,Fuentes Paige,Rizvi Hira,Egger Jacklynn V.,Kern Jeffrey A.,Leung Donald Y.M.,Lacouture Mario E.,Kris Mark G.,Gambarin Maya,Santomasso Bianca D.,Faleck David M.,Hellmann Matthew D.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance;Eagar;Eur J Immunol,2002

2. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline;Brahmer;J Clin Oncol,2018

3. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Haanen;Ann Oncol,2017

4. Treatment outcomes of immune-related cutaneous adverse events;Phillips;J Clin Oncol,2019

5. Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer;Owen;Clin Lung Cancer,2018

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

2. Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation;Science Translational Medicine;2024-06-12

3. Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study;Cancers;2024-05-16

4. Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19;Respiratory Investigation;2024-05

5. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors;European Journal of Cancer;2024-05